TBK1 Suppresses RIPK1-Driven Apoptosis and Inflammation during Development and in Aging
Author(s) -
Daichao Xu,
Taijie Jin,
Hong Zhu,
Hongbo Chen,
Dimitry Ofengeim,
Chengyu Zou,
Lauren Mifflin,
Lifeng Pan,
Palak Amin,
Wanjin Li,
Bing Shan,
Masanori Naito,
Huyan Meng,
Ying Li,
Heling Pan,
Liviu Aron,
Xian Adiconis,
Joshua Z. Levin,
Bruce A. Yankner,
Junying Yuan
Publication year - 2018
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2018.07.041
Subject(s) - biology , inflammation , apoptosis , microbiology and biotechnology , cancer research , genetics , immunology
Aging is a major risk factor for both genetic and sporadic neurodegenerative disorders. However, it is unclear how aging interacts with genetic predispositions to promote neurodegeneration. Here, we investigate how partial loss of function of TBK1, a major genetic cause for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) comorbidity, leads to age-dependent neurodegeneration. We show that TBK1 is an endogenous inhibitor of RIPK1 and the embryonic lethality of Tbk1 -/- mice is dependent on RIPK1 kinase activity. In aging human brains, another endogenous RIPK1 inhibitor, TAK1, exhibits a marked decrease in expression. We show that in Tbk1 +/- mice, the reduced myeloid TAK1 expression promotes all the key hallmarks of ALS/FTD, including neuroinflammation, TDP-43 aggregation, axonal degeneration, neuronal loss, and behavior deficits, which are blocked upon inhibition of RIPK1. Thus, aging facilitates RIPK1 activation by reducing TAK1 expression, which cooperates with genetic risk factors to promote the onset of ALS/FTD.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom